Diabetes

Miami, FL

89 Diabetes Trials near Miami, FL

Power is an online platform that helps thousands of Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

999 Participants Needed

This trial tests CagriSema, a combination of semaglutide and cagrilintide, in people with type 2 diabetes. It aims to see if it can better manage blood sugar levels and reduce body weight by increasing insulin and reducing hunger. Semaglutide is known for lowering blood glucose levels and reducing appetite.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

2734 Participants Needed

This trial is testing a special gel called ENERGI-F703 GEL to see if it can help heal foot ulcers in people with diabetes. The study focuses on patients with mild to moderate diabetic foot ulcers. The gel works by creating a good environment for skin repair and protecting the wound from germs. ENERGI-F703 gel, containing adenine as its active ingredient, has shown promise in accelerating wound healing in diabetic mice.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

230 Participants Needed

Tirzepatide for Type 2 Diabetes

Coral Gables, Florida
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

780 Participants Needed

This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites. The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM. The secondary objectives are to: 1. Assess the safety profile of siplizumab in recently diagnosed T1DM. 2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:8 - 45

120 Participants Needed

The purpose of this study is to test the hypothesis that allogeneic Mesenchymal Stem Cells (MSCs) promote systemic and coronary endothelial repair through rescue of bone marrow progenitors in type 2 diabetic patients with symptomatic IHD compared to placebo.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

30 Participants Needed

This trial is testing whether a combination of two drugs, rituximab-pvvr followed by abatacept, can better preserve insulin production in people newly diagnosed with Type 1 Diabetes compared to rituximab-pvvr alone. Rituximab-pvvr works by reducing harmful immune cells, while abatacept helps calm the immune system. The goal is to see if this combination can improve insulin production and overall diabetes management.
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:8 - 45

74 Participants Needed

This trial is testing a new drug called frexalimab in young people with newly diagnosed Type 1 Diabetes. The goal is to see if it can help their bodies keep making insulin. The study will compare different doses of the drug to find the safest and most effective amount.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 35

192 Participants Needed

This trial tests a new pill called BMF-219 that targets a protein named menin. It includes healthy adults and those with Type 2 Diabetes to see if it helps control blood sugar levels.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65

414 Participants Needed

This trial is testing the RESET System, a device placed in the stomach, to help people with Type 2 Diabetes and Obesity who haven't controlled their blood sugar well with current medications. The device works by reducing food absorption, aiding in better blood sugar control and weight loss. The RESET System has been shown to help with weight loss and better blood sugar control in patients with type 2 diabetes.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 65

264 Participants Needed

The goal of this mixed-methods study is to assess the impact of a Community Health Worker (CHW)-led social risk screening and referral in improving management of uncontrolled diabetes (DM) and hypertension (HTN) among patients receiving care in community health centers (CHCs or health centers). The intervention is focused on adult health center patients with uncontrolled DM and/or HTN. Study findings will provide important evidence to guide CHCs in implementing programs to address social risks in their patient populations. Findings will illuminate whether and how CHW-led interventions to address social needs yield the hypothesized outcomes. The aims of the study are: * AIM 1: Measure how effective the CHW-led social risk program is at reducing blood sugar levels (A1C) in CHC patients with uncontrolled DM and lowering blood pressure in CHC patients with uncontrolled HTN. * AIM 2: Identify effective strategies for increasing and expanding CHW-led social risk programs.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

3120 Participants Needed

This is a single-center, prospective, open label study in islet transplant recipients after complete islet graft rejection/loss, defined as stimulated c-peptide ≤0.3 ng/mL.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

18 Participants Needed

This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 70

264 Participants Needed

The goal of this clinical trial is to use continuous glucose monitoring (CGM) to quickly detect and manage high blood sugar in pregnant women, early in pregnancy. The main questions it aims to answer are: (1) any problems for the baby, such as being too large for their age, shoulder injuries (like broken bones), high bilirubin levels needing light treatment, low blood sugar, or needing to stay in the NICU; (2) any high blood pressure issues for the mother during pregnancy.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Sex:Female

6000 Participants Needed

This trial tests if using Diamyd and Vitamin D can help young people and adults with Type 1 Diabetes. The goal is to help their bodies keep making insulin for longer. High dose vitamin D and omega 3 have shown promise in prolonging remission in Type 1 Diabetes.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 28

330 Participants Needed

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17

55 Participants Needed

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1023 Participants Needed

This trial tests whether inclisiran injections can prevent serious heart problems in high-risk adults who haven't had a major heart event yet by lowering their cholesterol levels. Inclisiran is a long-acting treatment that significantly lowers cholesterol.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 79

14013 Participants Needed

This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

8600 Participants Needed

The intervention in this trial is intraocular islet transplantation. A single dose of 1000 - 3000 Islet Equivalents (IEQ)/kg recipient body weight (BW) will be infused into the anterior chamber of the eye through a self-sealing incision in the peripheral cornea. The procedure is projected to take approximately 20-30 minutes. Subject will remain flat on their back for 1 - 3 hours after islet infusion to maximize adhesion of the islets to the iris.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

2 Participants Needed

Why Other Patients Applied

"Years ago, Metformin didn't help. I'm currently on Rybelsus & Farxiga. Not doing me much good. My insurance won't cover any of the injectables. Excited to try something new."

QL
Diabetes PatientAge: 71

"I have had type 2 diabetes for some time now and would love to be part of a study... should the study drug work out as a successful treatment, then I would be glad to be one of the first patients in line!"

MB
Diabetes PatientAge: 67

"I have already lost part of a leg to an infection. I want to try to get this horrific condition under control and get back to my life. It's taken enough."

WY
Diabetes PatientAge: 40

"Looking for better ways to manage my diabetes, high blood pressure and overall health. Hoping to improve my health all together in order to have a better life & to enjoy my children & grandchildren."

OK
Diabetes PatientAge: 66

"I have struggled with weight management after having bariatric surgery over 5 years ago and have regained what I have lost. I'm looking to participate in a trial that can help me get my life back under control."

IJ
Diabetes PatientAge: 25
The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

230 Participants Needed

This trial is testing two medications, abrocitinib and ritlecitinib, which aim to reduce immune system activity. The study focuses on people who have been recently diagnosed with Stage 3 Type 1 Diabetes. These medications work by calming the immune system to prevent it from attacking insulin-producing cells in the pancreas.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 35

78 Participants Needed

This trial is testing ladarixin, a medication that may help protect insulin-producing cells in the pancreas. It targets adolescents and adults who have been diagnosed with type 1 diabetes, especially those with severe cases. The goal is to see if ladarixin can slow down the progression of the disease and keep these cells working longer.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:14 - 45

140 Participants Needed

A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:6 - 34

101 Participants Needed

This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

134 Participants Needed

The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

409 Participants Needed

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

360 Participants Needed

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65

7 Participants Needed

This trial is testing a new drug called ALN-KHK to see how safe it is and how the body processes it. They are also testing another drug called KHK to check its safety and effectiveness. The study targets patients who might benefit from these drugs, aiming to understand their safety and how they work in the body.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65

49 Participants Needed

This trial is testing CELZ-201, a new treatment for people who have just been diagnosed with Type 1 Diabetes. The treatment is given directly into the bloodstream to help control blood sugar levels.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 35

18 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Diabetes clinical trials in Miami, FL pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Diabetes clinical trials in Miami, FL work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Diabetes trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL for Diabetes is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Diabetes medical study in Miami, FL?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Diabetes clinical trials in Miami, FL?

Most recently, we added Bimagrumab + Tirzepatide for Obesity with Type 2 Diabetes, Orforglipron for Type 2 Diabetes and Obesity and Orforglipron for Obesity to the Power online platform.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security